WTF, AMRN.....# Stock
T*C
1 楼
Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier
this morning after its marketing website inadvertently circulated a report
that Amarin's AMR101, or Vascepa, will be approved. The company acknowledged
the error, saying that says no determination on AMR101 NDA has yet been
made by the FDA, adding that information on the site was outdated and should
not be relied on.
this morning after its marketing website inadvertently circulated a report
that Amarin's AMR101, or Vascepa, will be approved. The company acknowledged
the error, saying that says no determination on AMR101 NDA has yet been
made by the FDA, adding that information on the site was outdated and should
not be relied on.